The proportion of
CD15+LOX-1+ PMN-MDSCs is associated
with NSCLC prognosis and recurrence after surgery
To confirm the connection between
CD15+LOX-1+ PMN-MDSCs and NSCLC
prognosis, we detected the
CD15+LOX-1+ PMN-MDSC proportion in
PB of NSCLC patients before and after surgical operation. The data
showed that CD15+LOX-1+ PMN-MDSC
frequency decreased significantly at 3 months after surgery
(20.84±1.3420 vs 12.79±0.9396 %, P =0.0058) (Figure 3A).
Furthermore, we also measured the percentage of
CD15+LOX-1+ PMN-MDSCs in NSCLC
patients with or without recurrence after surgery. It was found that
frequency of circulating CD15+LOX-1+PMN-MDSCs decreased significantly in NSCLC patients without recurrence
compared to that in NSCLC patients with recurrence (13.76±0.9581 vs
19.91±0.7098 %, P =0.0076) (Figure 3B). In these cases, 11
samples could be traced from the NSCLC patients listed in Table 1, in
which there were 8 patients without recurrence and 3 patients with
recurrence. By comparing the
CD15+LOX-1+ PMN-MDSC proportion in
different groups, it was further confirmed that
CD15+LOX-1+ PMN-MDSCs were related
to NSCLC recurrence after surgery (9.944±1.569 vs 21.25±0.7963 %,P <0.0001) (Figure 3C). All these data confirm that
circulating CD15+LOX-1+ PMN-MDSC
frequency is associated with NSCLC prognosis and recurrence after
surgery.